A mass of studies have demonstrated that PPARγ agonists via inhibiting the expression of cyclinD1, cyclinB, cyclinE, CDK4 and CDK2 and increasing the expression of CDKN1A to prevent cell cycle from G1 to S phase to prohibit tumor cells proliferation [22–26]. This evidence concerns the gene CDK2 and neoplasm.